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In addition, diminished insulin sensitivity is not appropriately compensated for by ␤-cell function in individuals with hypomagnesemia, indicating that it could be linked to inadequate ␤-cell compensation (52) . Moreover, the presence of hypomagnesemia in healthy subjects attenuates insulin action (48) , and the administration of Mg 2ϩ to those subjects ameliorates the insulin resistance (19) . These clinical observations are supported by the finding of a significant inverse relationship between dietary Mg 2ϩ intake and the risk of developing diabetes (54) and the finding that a Mg 2ϩ -rich diet reduces the oxidative risk of developing diabetes by 34% in women and 33% in men (37) . Therefore, the elucidation of the molecular mechanisms underlying hypomagnesemia may contribute to the development of new clinical approaches to combat diabetes.
Among the suspected causes of hypomagnesemia, reduced Mg 2ϩ intake and loss of Mg 2ϩ from the gastrointestinal tract concomitant with diarrhea has been considered (45) . However, the presence of hypermagnesiuria even under the condition of hypomagnesemia suggests that urinary loss resulting from reduced reabsorption in the kidneys is a major cause of hypomagnesemia in diabetes (45) . Hypermagnesiuria is known to be evident even in the early phase of diabetic nephropathy, showing microalbuminuria without apparent proteinuria and a reduction of glomerular filtration (2, 12) . However, it has yet been determined whether hypermagnesiuria is a characteristic pathological feature of diabetic nephropathy or an indirect phenomenon associated with other renal disorders, such as interstitial impairment.
To maintain Mg 2ϩ balance in the human body, ϳ12 mmol Mg 2ϩ is absorbed daily from food and drinking water and 8 mmol is excreted in feces and 4 mmol in urine (56) . The kidneys have a central role in Mg 2ϩ metabolism because each day, 80 mmol Mg 2ϩ is reabsorbed in tubules from 84 mmol filtered by the glomeruli (17) . The major tubular subsegments for Mg 2ϩ reabsorption are the proximal tubules (PTs), thick ascending limb of Henle (TAL), and distal convoluted tubules (DCTs), which are responsible for reabsorbing 10 -30%, 40 -70%, and 5-10% of filtered Mg 2ϩ , respectively (17) . In the TAL, Mg 2ϩ is reabsorbed through a paracellular pathway formed by claudin-16 (paracellin-1) and claudin-19 in tight junctions (21) . Active transcellular salt reabsorption in this segment results in a lumen-positive transepithelial voltage driving the passive paracellular reabsorption of divalent cations such as Mg 2ϩ (1, 20) . It has been shown that genetic mutations of claudin-16 and claudin-19 cause an inherited renal disorder, familial hypermagnesiuria, hypomagnesemia with hypercalciuria and nephrocalcinosis, indicating that these molecules are critical for Mg 2ϩ reabsorption (30, 53) . In contrast, in DCTs, the transient receptor potential (TRP)M6 channel provides a transcellular pathway for Mg 2ϩ reabsorption (1, 31) , which is responsible for the final regulation of urine Mg 2ϩ output. Although the amount of reabsorbed Mg 2ϩ in this segment is not abundant, the DCT is a critical segment because TRPM6 mutation causes a genetic disorder with hypermagnesiuric hypomagnesemia (51) .
It is well established that the severity of tubulointerstitial nephropathy (TIN) is a major factor affecting the loss of kidney function (42, 49) , and TIN has a greater effect than glomerular injury on the progression to end-stage renal damage (16) . In diabetic nephropathy, TIN is also known to be concomitantly developed with glomerular injury (6) . Interestingly, hypermagnesiuria has been revealed to be highly correlated with the histological severity of TIN (11, 13) . However, to the best of our knowledge, there are no detailed studies on the correlation between TIN and hypermagnesiuria in diabetic nephropathy.
In the present study, we examined the changes in the expression of molecules involved in tubular Mg 2ϩ reabsorption using a fatty spontaneous type 2 diabetes rat model and assessed the correlation between hypermagnesiuria and the progression of TIN. The results revealed that the susceptible molecule resulting in the hypermagnesiuria in diabetes is TRPM6 in DCTs and that the development of hypermagnesiuria and that of TIN were dissociated. We believe that the present findings may indicate a possible role of the detection of hypermagnesiuria as a new parameter to assess the functional alteration of the kidneys in early diabetes and may also provide a new therapeutic strategy for the clinical management of diabetes mellitus.
MATERIALS AND METHODS
Animals and experimental design. Six-week-old male Otsuka LongEvans Tokushima fatty (OLETF) rats and Long-Evans Tokushima Otsuka (LETO) rats, controls for OLETF rats, were obtained from the Otsuka Pharmaceutical Tokushima Research Institute (Tokushima, Japan). The animal protocol was approved by the Animal Care and Use Committee of Saitama Medical University. For the entire experimental period, rats were housed individually and given free access to food (rodent standard pellet chow, CE-2, CLEA Japan, Tokyo, Japan) and water. The rats' blood pressure was measured by the tail-cuff method (BP98-A, Softron, Tokyo, Japan). After urine collection for 24 h, blood samples were obtained from the aorta, and the rats' kidneys were perfused with ice-cold PBS (pH 7.4) and quickly removed under anesthesia (50 mg/kg ip pentobarbital) at 16, 24, and 34 wks of age (n ϭ 6). For the biochemical analysis of blood and urine samples, except Mg 2ϩ , all were measured according to published methods (3, 57) . Serum and urine Mg 2ϩ concentrations were measured by colorimetric tests using xylidine blue. The measurement of all biochemical parameters was consigned to SRL (Tachikawa, Tokyo, Japan).
Histology and immunohistochemistry. Kidneys were snap frozen in liquid nitrogen. Frozen sections (4 m) were incubated with rabbit anti-claudin-16 antibody (1:500, Invitrogen/Life Technologies, Carlsbad, CA) for 16 h at 4°C. Alexa fluor 488 donkey anti-rabbit IgG (HϩL, Invitrogen/Life Technologies) was subsequently applied as a second antibody to sections for 60 min at room temperature. Subsequently, after a wash, Alexa fluor 594 mouse anti-zonula occludens-1 antibody (1:200, Invitrogen/Life Technologies) as a third antibody was applied to sections for 60 min at room temperature. Other tissue blocks of kidneys were fixed in PBS containing 4% formaldehyde and embedded in paraffin. Sections (4 m) were prepared and stained with periodic acid-Schiff and Masson trichrome. Immunohistochemical stainings were performed as previously described (3) . The other paraffin sections were treated with primary antibody, rabbit anti-TRPM6 (Osenses, Keswick, SA, Australia), diluted 1:15,000, rabbit anti-Na ϩ -Cl Ϫ cotransporter (NCC; Merck, Darmstadt, Germany), diluted 1:8,000, mouse anti-␣-smooth muscle actin (␣-SMA; Progen Biotechnik, Heidelberg, Germany), diluted 1:2,500 for 16 h at 4°C, or mouse anti-Na ϩ -Ca 2ϩ exchanger 1 (NCX1; Swant Swiss Antibodies, Marly, Switzerland) diluted 1:2,000 for 1 h at room temperature followed by Dako Cytomation EnVision plus System HRP-Labeled Polymer (Dako, Glostrup, Denmark) or Histofine Simple Stain Rat MAX PO (M) (Nichirei Biosciences, Tokyo, Japan). A synthetic peptide from region 1970 -2020 of the rat TRPM6 amino acid sequence, corresponding to "CGKLRLPDLKRNDYSHARAHCNLE-LAKTTEPAEEHPERDRNRSPLEDHTRL," conjugated to an immunogenic carrier protein, was used as the antigen. To confirm the specificity of anti-TRPM6 antibody to TRPM6 protein, TRPM6 antibody was preabsorbed with control peptide (2.5 g/ml, Osenses) for 2 h at room temperature. A liquid diaminobenzidine substrate chromogen system was used for visualization with counterstaining by hemotoxylin. The interstitial area was analyzed by subtracting the tubules, glomerulus, and blood vessels from the total area and then dividing by the total area as previously reported (62) . We also semiquantitatively assessed the immunoreactivities of TRPM6, NCC, and NCX1 by referring to Ledeganck's method (32) . The diaminobenzidine-stained area was measured as a percentage of each field from the cortex. All analyses were performed using Image J computer program (1.43u, National Institutes of Health).
Gene expression analysis. Total RNA was extracted from the whole kidney, and real-time PCR was use for the assessment of gene expression as previously described (57) . TaqMan probes and primers for claudin-16 [assay identifier (ID): Rn00590884_m1], TRPM6 (assay ID: Rn01760130_m1), TRPM7 (assay ID: Rn00586779_m1), Na ϩ -K ϩ -2Cl Ϫ cotransporter (NKCC)2 (assay ID: Rn00569491_m1), NCC (assay ID: Rn00571074_m1), monocyte chemotactic protein-1 (assay ID: Rn00580555_m1), and ␣-SMA (assay ID: Rn01759928_g1) were applied to TaqMan Gene Expression Assays (Applied Biosystems, Foster City, CA). TaqMan real-time PCR probe and primers for Na ϩ /H ϩ exchanger (NHE)3 were designed using PrimerExpress software (Applied Biosystems, NHE3 probe: 5=-FAM-CTTCAGCA-CACCCCGCCCATCTAC-TAMRA-3=, forward primer: 5=-TCCC-CAAGTACGGACAATATGG-3=, and reverse primer: 5=-GCAC-TGACATTTTCCCTCAAGAA-3=). We used the expression of rat actin-␤ (Rat ACTB Endogenous Control VIC/MGB Probe, Applied Biosystems) as an internal control for correction of sample variability. We evaluated the expression of each gene by the ⌬Ct method, where C t is threshold cycle, as previously described (3).
Statistical analysis. Results are presented as means Ϯ SE in each group. Student's two-tailed t-test was used to compare data between OLETF and LETO rats. Corrected kidney weight, serum Mg 2ϩ , plasma glucose, and insulin at 16, 24, and 34 wk of age were compared with one-way ANOVA followed by Bonferroni's post hoc test. P values of Ͻ0.05 were considered significant. All analyses were performed using SPSS (version 20.0) for Windows XP (IBM, Armonk, NY). 
RESULTS
The results of the blood and urine tests are shown in Table 1 . Body weights of OLETF rats were significantly larger than those of LETO rats at all ages. The mean blood pressure of OLETF rats was also higher than that of LETO rats. Corrected kidney weights of OLETF rats were decreased with week age (i.e., 16, 24, and 34 wk of age), and they were significantly higher than those of LETO rats at 24 and 34 wk old. Serum creatinine levels of OLETF rats were significantly lower than those of LETO rats at all week ages, reflecting the difference of glomerular filtration due to an increase in the extracellular fluid (ECF) volume.
Hyperglycemia and hyperinsulinemia in OLETF rats were significant at all week ages, although differences between each week age were not observed. Urine Mg 2ϩ excretion, assessed by the absolute amount of urine Mg 2ϩ output (UMgV; in g·min Ϫ1 ·100 g body wt Ϫ1 ), as previously reported (22), was significantly increased after 24 wk, and significant hypomagnesemia compared with LETO rats was apparent in 34-wk-old OLETF rats. In accordance, the fractional excretion of Mg 2ϩ (FEMg) was also significantly increased at 24 and 34 wk. The urine albumine-to-creatinine ratio was significantly high in OLETF rats at all week ages. Even at 16 wk old, OLETF rats showed significant albuminuria, indicating that the early phase of OLETF in this study might correspond to the microalbuminuric stage of diabetic nephropathy. In addition, urine glucose excretion corrected by body weight (UGluV) was significantly high in LETO rats at 16 wk; however, urine excretion of Mg 2ϩ (UMgV and FEMg) and urine excretion of Na ϩ [absolute amount of urine Na ϩ output (UNaV) and fraction excretion of Na ϩ (FENa)] were not different between LETO and OLETF rats. In contrast, UMgV and FEMg were significantly high in OLETF rats, although there was no significant difference in UGluV, UNaV, and FENa between LETO and OLETF rats at both 24 and 34 wk. Serum Mg 2ϩ concentrations were not different among all week ages in both LETO and OLETF rats.
As shown in Fig. 1A , expression of claudin-16 mRNA did not differ significantly between LETO and OLETF rats throughout the experimental period, without time-differential changes in mRNA expression in both LETO and OLETF rats (16 wk: 100.1 Ϯ 2.8% in LETO rats and 87.0 Ϯ 4.6% in OLETF rats, 24 wk: 89.5 Ϯ 4.6% in LETO rats and 100.9 Ϯ 3.5% in OLETF rats, and 34 wk: 90.4 Ϯ 4.5% in LETO rats and 100.9 Ϯ 3.6% in OLETF rats, n ϭ 6, respectively). Dual immunostaining with claudin-16 and zonula occludens-1 antibodies was preceded and conducted to confirm whether the used claudin-16 antibody properly recognized claudin-16 in the tight junction (Fig. 1B) . As described in a previous report using the same antibody (24), the majority of both signals were colocalized in the basolateral side of the TAL. Immunofluorescent staining of claudin-16 also did not show any apparent difference between LETO and OLETF rats throughout the experimental period (Fig. 1C) .
We next studied the expression of Mg 2ϩ -transporting molecules, located principally in DCTs. Figure 2 shows significant and stable inhibition of mRNA expression of TRPM6 in OLETF rats (16 wk: 100.1 Ϯ 3.3% in LETO rats and 59.9 Ϯ 1.7% in OLETF rats, 24 wk: 92.0 Ϯ 5.1% in LETO rats and 61.6 Ϯ 1.5% in OLETF rats, and 34 wk: 85.5 Ϯ 5.6% in LETO rats and 63.0 Ϯ 3.5% in OLETF rats, n ϭ 6, respectively), whereas mRNA expression of TRPM7 did not differ during the experimental period (16 wk: 100.2 Ϯ 3.3% in LETO rats and 109.6 Ϯ 4.6% in OLETF rats, 24 wk: 106.2 Ϯ 2.7% in LETO rats and 114.5 Ϯ 4.5% in OLETF rats, and 34 wk: 127.2 Ϯ 3.1% in LETO rats and 130.3 Ϯ 3.3% in OLETF rats, n ϭ 6, respectively). We also studied mRNA expression of molecules that might affect tubular Mg 2ϩ reabsorption. mRNA expression of both NHE3 and NKCC2 showed no significant differences between LETO and OLETF rats in all of the experimental periods (NHE3: 100.5 Ϯ 5.2% in LETO rats and 110.7 Ϯ 7.2% in OLETF rats at 16 wk, 95.5 Ϯ 4.8% in LETO rats and 108.8 Ϯ 4.9% in OLETF rats at 24 wk, and 105.9 Ϯ 4.6% in LETO rats and 116.1 Ϯ 3.2% in OLETF rats at 34 wk, n ϭ 6, respectively; and NKCC2: 100.0 Ϯ 1.8% in LETO rats and 78.8 Ϯ 8.5% in OLETF rats at 16 wk, 78.1 Ϯ 4.4% in LETO rats and 89.8 Ϯ 4.6% in OLETF rats at 24 wk, and 76.7 Ϯ 3.7% in LETO rats and 85.2 Ϯ 2.6% in OLETF rats at 34 wk, n ϭ 6), respectively.
Before assessing the difference in TRPM6 protein expression by immunostaining, we checked the specificity of the anti-TRPM6 antibody. As shown in Fig. 3A , when TRPM6 antibody was preabsorbed with control peptide, no apparent immunoreactivity was detected, indicating that the antibody would specifically recognize TRPM6 protein, as previously demonstrated. The localization of TRPM6 immunoreactivity was confirmed by concomitant immunostaining with NCX1, which is known to be principally expressed on the basolateral plasma membrane of DCTs. The TRPM6 signal was detected in the common tubules, which were stained by NCX1 antibody in serial sections (Fig. 3B) . We qualitatively evaluated the protein expression of TRPM6 by immunohistochemistry using low-magnified kidney transverse sections. As shown in Fig.  3C , TRPM6 immunoreactivity in OLETF sections was evidently low compared with LETO sections, a finding that was consistent with the results of our mRNA expression analysis.
Observation under high magnification showed that the positive signals of TRPM6 observed in the cortex of OLETF rats were markedly diminished or nearly disappeared in the LETO cortex (Fig. 4A) . Since the thiazide-sensitive NCC is known to be a major regulator of TRPM6 expression (44), we also evaluated its expression profile. As shown in the representative micrographs, the cortical signals of NCC were clearly diminished in OLETF sections (Fig. 4B) , a result that is consistent with the significant downregulation of NCC mRNA (Fig. 4C) . For the semiquantitative assessment of the immunoreactivities of TRPM6 and NCC, we measured the positive area of these immunoreactivities by computer-assisted imaging analysis on multiple sections using pictures converted to monochrome two-gradation (postconversion), as shown in the representative pictures in Fig. 4D , top. As a result, both positive areas were significantly and simultaneously decreased in OLETF rats at all week ages (TRPM6: 0.49 Ϯ 0.04% in LETO rats and 0.10 Ϯ 0.01% in OLETF rats at 16 wk, 0.52 Ϯ 0.03% in LETO rats and 0.10 Ϯ 0.01% in OLETF rats at 24 wk, and 0.48 Ϯ 0.02% in LETO rats and 0.12 Ϯ 0.02% in OLETF rats at 34 wk; NCC: 1.59 Ϯ 0.09% in LETO rats and 0.77 Ϯ 0.05% in OLETF rats at 16 wk, 1.69 Ϯ 0.13% in LETO rats and 0.84 Ϯ 0.05% in OLETF rats at 24 wk, and 1.99 Ϯ 0.13% in LETO rats and 0.80 Ϯ 0.06% in OLETF rats at 34 wk; Fig. 4D, bottom) . However, as shown in Fig. 5A , apparent differences in the morphology of DCTs were not observed between LETO and OLETF rats. In addition, protein expression of NCX was semiquantitatively analyzed by measurements of the relative area of NCX immunoreactivity to rule out the possibility that the membrane protein might be generally diminished in DCTs of OLETF rats. As shown in Fig. 5 , B and C, no significant difference in NCX expression was detected between LETO and OLETF rats.
Finally, to evaluate the correlation between TRPM6 expression and TIN, we measured the relative change in the interstitial area. As shown in representative micrographs (Fig. 6A) , expansion of the interstitial area in OLETF rats was not evident compared with that in LETO rats at all week ages, and the statistical analysis among multiple measurements of the relative interstitial area confirmed that there were no significant differences between LETO and OLETF data (Fig. 6B) . We also studied the mRNA expression of proinflammatory cytokines related to interstitial fibrosis for the assessment of the development of TIN (Fig. 6C) . mRNA expression of both monocyte chemotactic protein-1 and ␣-SMA did not differ significantly between LETO and OLETF rats throughout the experimental period (Fig. 6C) . Finally, we confirmed the difference of protein expression of ␣-SMA by immunostaining. As shown in Fig. 6D , there was no apparent difference of ␣-SMA expression between LETO and OLETF rats.
DISCUSSION
OLETF rats are generally known to show hyperinsulinemia and microalbuminuria at ϳ18 wk of age, apparent proteinuria at 25-30 wk (10), and histological changes in the glomeruli, including membrane thickening or mesangeal matrix expansion, after 40 wk of age (26) . Although the week ages of OLETF rats cannot be simply compared with the clinical stages of human diabetic nephropathy, the 16-, 24-, and 34-wk-old OLETF rats used in this study would roughly correspond to the early phase with microalbuminuria, the midphase with apparent proteinuria, and the preadvanced phase without histological alterations, respectively. Hence, time-differential changes in diabetic nephropathy at various stages could be roughly assessed using this animal model.
To avoid the influence of endogenous creatinine clearance being less reliable in rodents for the present evaluation of glomerular filtration, we assessed the rats' urine Mg 2ϩ excretion by the absolute amount of urine Mg 2ϩ output (UMgV) following Hou et al.'s method (22) . According to Hou et al., UMgV is shown to be altered with a positive correlation to FE Mg , indicating the validity of this parameter for the assessment of urine Mg 2ϩ excretion (22) . In fact, calculated FEMg using inulin clearance showed similar differences between LETO and OLETF rats to UMgV (22) .
In the present study, a significant increase in urine Mg 2ϩ excretion was present before the appearance of apparent proteinuria, and significant hypomagnesemia was evident in OLETF rats at 34 wk with the increase in urine Mg 2ϩ excretion. However, there were no significant differences in serum Mg 2ϩ concentrations among all week age groups in LETO or OLETF rats.
These observations might indicate that OLETF rats well represented the generally observed hypermagnesiuria in early diabetic nephropathy and resultant hypomagnesemia in humans. It is generally believed that the urine volume or ECF volume significantly affects renal Mg 2ϩ excretion. The results of the present study showed that the urine volume in OLETF rats was significantly increased only among 34-wk-old rats, although a significant increase in UMgV was demonstrated in both 24-and 34-wk-old rats. Likewise, a significantly low plasma aldosterone concentration, suggesting increased ECF volume, was observed only in 34-wk-old OLETF rats. These discrepancies do not straightforwardly deny the possible involvement of urine volume or ECF volume in renal Mg 2ϩ excretion, but they strongly suggest that one or more factors that are independent of the effect of urine or ECF volume, or factors that enhance these effects, are involved in the development of hypermagnesiuria in diabetic nephropathy. In addition, urine Mg 2ϩ excretion in OLETF rats was higher than that in LETO rats. However, urine Na ϩ and glucose excretion were not significantly different between the two groups, which strongly suggests that urine Mg 2ϩ excretion would be regu- lated independently of Na ϩ or glucose excretion in this diabetic model.
The contribution of DCTs to the amount of reabsorbed Mg 2ϩ is lesser than that of the TAL. However, it has been elucidated that a loss of function mutation of TRPM6 in patients with primary hypomagnesemia with secondary hypocalcemia results in renal Mg 2ϩ wasting (50) or an inappropriate elevation of the fractional Mg 2ϩ excretion rate with respect to their low serum Mg 2ϩ levels (51), indicating that the diminished Mg 2ϩ reabsorption in DCTs sufficiently evokes hypermagnesiuria by decreased reabsorption through TRPM6.
Although the regulatory mechanisms of TRPM6 expression have not been fully elucidated, interactions between altered TRPM6 expression and various disease settings or drug effects have been identified.
For instance, EGF functions as a positive regulator of TRPM6 (58) , and the anti-EGF receptor antibody cetuximab causes hypomagnesemia by impeding EGF-dependent activation of TRPM6 (60) . Similarly, hypomagnesemia concomitant with cyclosporin A administration is now known to be caused principally by cyclosporin-induced downregulation of TRPM6 (23) . The upregulation of TRPM6 by a Mg 2ϩ -deficient diet for the semiquantitative assessment of immunoreactivities of both TRPM6 and NCC, original pictures (preconversion) were converted to monochrome two-gradation pictures (postconversion), and we measured the positive area (black) and calculated the occupying ratio to the entire field of each picture. We used the average value of measurement of eight randomly selected microscopic fields (magnification: ϫ100) in each animal in the statistical analysis of six animals. Open bars indicate LETO rats; solid bars indicate OLETF rats. Data are means Ϯ SE; n ϭ 6. *P Ͻ 0.05; **P Ͻ 0.01. (47) and by inhibition of aldosterone-induced downregulation of TRPM6 by Mg 2ϩ supplementation (55) have also been demonstrated. Taken together, all of the experimental evidence indicates that the downregulation of TRPM6 in the present study would sufficiently cause hypermagnesiuric hypomagnesemia in diabetic nephropathy.
Future studies should investigate the involvement of extracellular glucose and insulin concentration, osmolality, Na ϩ concentration, advanced glycation end products, and nitric oxide in the regulation of TRPM6. In general, changes in the expression or activity of Mg 2ϩ -transporting molecules (claudin-16/19 or TRPM6/M7) are not indispensable for the increase or decrease in Mg 2ϩ absorption in the TAL and PTs. The lumen-positive charge generated by the functional coupling of Na ϩ absorption and K ϩ excretion in the TAL is a driving force for paracellular Mg 2ϩ absorption through claudin-16/19 in tight junctions of the TAL. Diminished NKCC2 expression might cause the reduction of the lumen-positive charge, and the increase in NHE3 expression or activity in PTs might diminish passive Mg 2ϩ absorption in PTs and might also decrease Na ϩ delivery into the TAL, with a resultant reduction of Na ϩ absorption and lumenpositive charge. However, no significant changes of mRNA levels of NKCC2 and NHE3 were observed in this study, suggesting that the changes in urine Mg 2ϩ excretion in OLETF rats would be predominantly provoked by the altered expression of TRPM6 in DCTs.
The chronic administration of thiazide is well known to induce hypomagnesemia concomitant with NCC downregulation (44) . Additionally, hypomagnesemia is one of the major clinical features in Gitelman syndrome, a hereditary disorder caused by a loss of function mutation of NCC, which indicates a significant reduction of TRPM6 expression resulting in hypomagnesemia (35, 44) . In the present study, gene and protein expressions of NCC were significantly diminished, a result that is consistent with the downregulation of TRPM6 through the entire experimental period, suggesting the possible contribution of NCC downregulation to decreased TRPM6 expression. In addition, Loffing et al. (36) reported the structural damage of DCT cells in NCC-deficient mice and thiazide-treated rats. However, our observations of no significant differences in DCT morphology and NCX protein expression in the present study showed the lesser possibility of the involvement of the structural damage in DCTs of OLETF rats. The presumed interaction between NCC and TRPM6 expression was also indicated by Ledeganck et al. , who demonstrated TRPM6 downregulation and a simultaneous reduction of NCC expression as a major cause of hypomagnesemia in cases of cyclosporin administration (32) . Moreover, it is generally accepted that the phosphorylation of NCC by members of the WNK family (especially WNK4) via Ste20-related proline-alaninerich kinase/oxidative stress-responsive kinase-1 plays a central role in the regulation of NCC activity and/or sorting to the membrane surface (14, 29) . However, roles have been de- scribed for vasopressin (15, 41) and aldosterone (39, 43) as regulators of NCC transcription.
In the present study, we did not investigate the regulatory mechanism of NCC downregulation in detail, and we observed no differences in aldosterone levels (Table 1) , plasma antidiuretic hormone concentrations, or expression of WNK4 (data not shown) between OLETF and LETO rats. At present, the expression profile of NCC in rodent diabetic models is controversial. Although some studies (5, 27) using obese Zucker rats exhibiting diabetes have described a significant increase in the protein expression of NCC, another study (4) using the same model reported no difference in NCC protein expression. Interestingly, Madala et al. (38) reported that NCC expression was declined by 50% in Zucker fatty rats, whereas renin-aldosterone levels were not significantly different, findings that are consistent with those of the present study. Similarly, Riazi et al. (46) revealed that in Zucker fatty rats, acute salt loading induces a significant reduction of NCC expression, whereas aldosterone does not respond to the salt load.
Although the precise mechanism of NCC downregulation was not demonstrated in the present study, the fact that the expression profile of NCC in diabetes was not consistently established in the multiple studies described here, even though the studies used the same model, may correspond to the clinical variation observed, that is, not all diabetic patients show hypomagnesemia. The expression of NCC is highly regulated by aldosterone, indicating that hypermagnesiuria through inhibition of TRPM6-NCC would be influenced by differences in the phenotype of each model animal or experimental conditions in animal experiments and by differences in the fluid volume status or living conditions of patients. The specific conditions resulting in the downregulation of TRPM6 remain to be elucidated.
Since TRPM6 forms a functional ion channel complex with TRPM7 (7), we investigated potential changes in TRPM7 expression, and we did not detect a significant alteration in this study. It appears that the regulatory mechanism and tissue distribution of TRPM6 and TRPM7 may be entirely different. For instance, TRPM6 is selectively expressed in the kidney, lung, cecum, and colon, whereas TRPM7 is located throughout the body (18) . Mg 2ϩ restriction strongly induces upregulation of TRPM6 in the kidney but does not affect TRPM7 (18) . Yogi et al. (61) reported that TRPM7 expression is not affected in the condition of decreased Mg 2ϩ concentration in the ECF, whereas this condition induces a downregulation of TRPM6 and enhances urine Mg 2ϩ excretion. These results clearly indicate that the expressions of TRPM6 and TRPM7 are independently regulated. It is thus understandable that the expressions of TRPM6 and TRPM7 in the present study showed different profiles in OLETF rats, a result that is consistent with those of several previous studies.
In contrast to our results, Lee et al. (33) reported upregulation of TRPM6 and NCC and no difference in claudin-16 expression in streptozotocin-induced diabetic rats. According to their results, urine Mg 2ϩ excretion should be de- creased, although they also observed an increase in urine Mg 2ϩ excretion with no change in serum Mg 2ϩ concentration. Basically, streptozotocin-induced diabetes is a type 1 diabetic model lacking pancreatic insulin secretion. OLETF is a type 2 diabetic model showing hyperinsulinemia. It is thus difficult to compare the results from these two models, and our results should be assessed independently of the results of Lee et al.
In addition, Nair et al. (41) reported that insulin activates membrane trafficking of TRPM6 to the cell surface and stimulates Mg 2ϩ current in human embryonic kidney-293T cells. These observations suggest that insulin would stimulate Mg 2ϩ uptake into cells in vitro. However, an acceleration of Mg 2ϩ transport by insulin was not directly demonstrated in that study, and an action of insulin on Mg 2ϩ excretion from kidneys in animals or humans was not shown. The functional correlation between insulin and hypermagnesiuric hypomagnesemia in diabetic patients is still obscure.
We recently studied the molecular mechanisms of hypermagnesiuric hypomagnesemia in TIN, which is the other major disease setting showing hypermagnesiuric hypomagnesemia. In contrast to the present results, a rat model showing glomerular injury-independent TIN demonstrated significant downregulation of claudin-16 in parallel with the development of interstitial damage and hypermagnesiuric hypomagnesemia (T. Shimizu and H. Hasegawa, unpublished observations). These preliminary data might also indicate that TRPM6-induced hypermagnesiuric hypomagnesemia is a characteristic feature of altered tubular function in early diabetic nephropathy. The present results indicate that hypermagnesiuria in diabetic nephropathy would be caused principally by the attenuated Mg 2ϩ reabsorption through TRPM6 in DCTs, which is not generally observed in nondiabetic animals. The findings of the present study may provide a scientific background for the usefulness of the assessment of Mg 2ϩ excretion as a clinical parameter of tubular impairment in early diabetic patients in combination with the assessment of microalbuminuria, a parameter of early glomerular injury. The present findings also provide a rationale for the clinical approach of active Mg 2ϩ supplementation to inhibit the development of insulin resistance and/or coronary disease.
In summary, the results of the present study showed significant and TIN-independent downregulation of TRPM6 as a possible cause of hypermagnesiuric hypomagnesemia in early diabetic nephropathy, suggesting that the detection of hypermagnesiuria may be a beneficial parameter for the assessment of functional changes in renal tubules in early diabetic nephropathy. In addition, therapeutic approaches to the functional alteration in DCTs may be a new strategy for the restoration of insulin resistance.
